• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 84-98 of 313 results

6 Power of Attorney: Power of Attorney from Patent Owner Almirall, LLC

Document IPR2019-00207, No. 6 Power of Attorney - Power of Attorney from Patent Owner Almirall, LLC (P.T.A.B. Feb. 5, 2019)
The undersigned has the authority to execute this document on behalf of Patent Owner Almirall, LLC.
Date: January 9, 2019 Name: Ron Menezes Title: President and General Manager, Almirall, LLC
Almirall, LLC, states that, for the patent identified above, it is the assignee of the entire right, title, and interest.
That interest is evidenced by a chain of title from the inventors of the patent identified above to the current assignee as follows: 1.
Date: January 9, 2019 Name: Ron Menezes Title: President and General Manager, Almirall, LLC
cite Cite Document
Analyze

5 Mandatory Notice: Patent Owner Almirall, LLCs Mandatory Notices Under 37 CFR Section 428

Document IPR2019-00207, No. 5 Mandatory Notice - Patent Owner Almirall, LLCs Mandatory Notices Under 37 CFR Section 428 (P.T.A.B. Jan. 10, 2019)
Log in to see more
cite Cite Document
Analyze

2 Exhibit List: 219 Exhibit List

Document IPR2019-00207, No. 2 Exhibit List - 219 Exhibit List (P.T.A.B. Nov. 6, 2018)
Log in to see more
cite Cite Document
Analyze

1 Power of Attorney: Power of Attorney

Document IPR2019-00207, No. 1 Power of Attorney - Power of Attorney (P.T.A.B. Nov. 6, 2018)
Log in to see more
cite Cite Document
Analyze

1020 Exhibit: Affidavit of Christopher Butler

Document IPR2019-01095, No. 1020-19 Exhibit - Affidavit of Christopher Butler (P.T.A.B. Jun. 7, 2019)
Log in to see more
cite Cite Document
Analyze

1007 Exhibit: US Patent Publication No 20060204526 Lathrop

Document IPR2019-01095, No. 1007-7 Exhibit - US Patent Publication No 20060204526 Lathrop (P.T.A.B. Jun. 7, 2019)
Log in to see more
cite Cite Document
Analyze

1016 Exhibit: US Patent No 5,863,560 Osborne II

Document IPR2019-01095, No. 1016-16 Exhibit - US Patent No 5,863,560 Osborne II (P.T.A.B. Jun. 7, 2019)
Log in to see more
cite Cite Document
Analyze

1022 Exhibit: Wozel, D, Innovative Use of Dapsone Dermatol Clin 28 599 610 2010 Wozel

Document IPR2019-01095, No. 1022-20 Exhibit - Wozel, D, Innovative Use of Dapsone Dermatol Clin 28 599 610 2010 Wozel (P.T.A.B. Jun. 7, 2019)
Log in to see more
cite Cite Document
Analyze

1004 Exhibit: International Patent Application Publication No WO 2009061298 Garrett

Document IPR2019-01095, No. 1004-4 Exhibit - International Patent Application Publication No WO 2009061298 Garrett (P.T.A.B. Jun. 7, 2019)
Currently, use of oral dapsone is generally limited to more severe forms of skin disease, as its use may be associated with hematologic side effects, including hemolysis and hemolytic anemia that are dose-dependent and occur more 15 frequently with increasing dose (Zhu and Stiller 2001; Jollow et al., 1995).
Some 30 preservatives useful in this invention include methylparaben, propylparaben, butylparaben, chloroxylenol, sodium benzoate, DMDM Hydantoin, 3-Iodo-2- Propylbutyl carbamate, potassium sorbate, chlorhexidine digluconate, or a combination thereof.
15 In a more preferred embodiment, the dermatological composition that is applied comprises about 0.85% carbomer, about 66.95% water, about 25% diethylene glycol monoethyl ether (i.e., ethoxydiglycol), about 0.2% methylparaben, about 5% dapsone, and about 0.2% sodium hydroxide solution.
Thus, the carrier system described herein, 5 which can be adjusted to optimize the delivery profile for the pharmacology of the active drug and the nature of the disease state, advances the effectiveness of pharmaceutical products applied to the skin of G6PD-deficient patients.
Furthermore, the low haptoglobin was present at the baseline blood test as well as week 12, and no other changes in the other hematology parameters occurred, so the laboratory adverse events for this subject are likely not related to dapsone gel treatment.
cite Cite Document
Analyze

1028 Exhibit: Remington The Science and Practice of Pharmacy, 21st Ed, Lippincott Williams Wilkins Baltimore, MD 2005 Remington

Document IPR2019-01095, No. 1028-26 Exhibit - Remington The Science and Practice of Pharmacy, 21st Ed, Lippincott Williams Wilkins Baltimore, MD 2005 Remington (P.T.A.B. Jun. 7, 2019)
cite Cite Document
Analyze

1035 Exhibit: Declaration of Audra L Stinchcomb, PhD

Document IPR2019-01095, No. 1035-31 Exhibit - Declaration of Audra L Stinchcomb, PhD (P.T.A.B. Jun. 7, 2019)
Log in to see more
cite Cite Document
Analyze

1036 Exhibit: Curriculum Vitae for Audra L Stinchcomb, PhD

Document IPR2019-01095, No. 1036-32 Exhibit - Curriculum Vitae for Audra L Stinchcomb, PhD (P.T.A.B. Jun. 7, 2019)
Log in to see more
cite Cite Document
Analyze

1013 Exhibit: US Patent Publication No 20070190019 Guo

Document IPR2019-01095, No. 1013-13 Exhibit - US Patent Publication No 20070190019 Guo (P.T.A.B. Jun. 7, 2019)

cite Cite Document
Analyze

1026 Exhibit: SepineoTM P 600 Brochure

Document IPR2019-01095, No. 1026-24 Exhibit - SepineoTM P 600 Brochure (P.T.A.B. Jun. 7, 2019)

cite Cite Document
Analyze

1003 Exhibit: Curriculum Vitae for Bozena B Michniak Kohn, PhD, FAAPS, MRPhar...

Document IPR2019-01095, No. 1003-3 Exhibit - Curriculum Vitae for Bozena B Michniak Kohn, PhD, FAAPS, MRPharmS (P.T.A.B. Jun. 7, 2019)

cite Cite Document
Analyze
<< 1 2 3 4 5 6 7 8 9 10 ... >>